Site sequence number,Site code,Subject sequence number,Subject Id,Event sequence number,Event Id,Event name,Event date,Activity Id,Activity name,Form Id,Form name,Form sequence number,Subject form sequence number,Origin Subject form sequence number,Source Subject form sequence number,Item group Id,Item group sequence number,Item Id,Item export label,Design version,Item value,Item code,Edit datetime (UTC),Edit by,Edit reason
SiteSeq,SiteCode,SubjectSeq,SubjectId,EventSeq,EventId,EventName,EventDate,ActivityId,ActivityName,FormId,FormName,FormSeq,SubjectFormSeq,OriginSubjectFormSeq,SourceSubjectFormSeq,ItemGroupId,ItemGroupSeq,ItemId,ItemExportLabel,DesignVersion,ItemValue,ItemCode,EditDateTime,EditBy,EditReason
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG3,1,RS_PERF,Was the Response Assessment performed?,50.0,Yes,1,2023-01-09 08:25,DM1,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG3,1,RS_RSDAT,Date of Response Assessment,50.0,2022-05-08,NA,2023-01-09 08:25,NA,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_DIS,Disease Response,50.0,CR with incomplete hematologic recovery (CRi),2,2023-01-09 08:25,DM3,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_HEM1,Hematological Improvement - 1,50.0,Erythroid response (HI-E),1,2023-01-09 08:25,DM1,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_HEM2,Hematological Improvement - 2,50.0,NA,NA,2023-01-09 08:25,NA,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_HEM3,Hematological Improvement - 3,50.0,NA,NA,2023-01-09 08:25,DM3,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_HEM4,Hematological Improvement - 4,50.0,NA,NA,2023-01-09 08:25,DM2,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG2,1,RS_RESP_HEM_SPEC,Specify type of Erythroid response (HI-E),50.0,Based on NTD (0 RBCs in 16 wk) at baseline,1,2023-01-09 08:25,NA,Initial Data Entry
3,9600,2,9600-002,9,VIS9,Study Visit (Primary Treatment Phase),2022-05-08,VIS_RS,NA,RS,Response Assessment,1,1,1,NA,RSG1,1,RS_DSRESP,Is the subject classified to be a Responder according to protocol?,50.0,Yes,1,2023-01-09 08:25,NA,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG3,1,RS_PERF,Was the Response Assessment performed?,50.0,Yes,1,2023-01-09 08:29,NA,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG3,1,RS_RSDAT,Date of Response Assessment,50.0,2022-09-11,NA,2023-01-09 08:29,DM1,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_DIS,Disease Response,50.0,Complete remission (CR),1,2023-01-09 08:29,DM3,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_HEM1,Hematological Improvement - 1,50.0,Erythroid response (HI-E),1,2023-01-09 08:29,NA,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_HEM2,Hematological Improvement - 2,50.0,NA,NA,2023-01-09 08:29,DM3,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_HEM3,Hematological Improvement - 3,50.0,NA,NA,2023-01-09 08:29,DM3,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_HEM4,Hematological Improvement - 4,50.0,NA,NA,2023-01-09 08:29,DM3,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG2,1,RS_RESP_HEM_SPEC,Specify type of Erythroid response (HI-E),50.0,Based on NTD (0 RBCs in 16 wk) at baseline,1,2023-01-09 08:29,DM2,Initial Data Entry
3,9600,2,9600-002,8,VISEXT8,Study Visit (Extension Treatment Phase),2022-09-11,VIS2_RS,NA,RS,Response Assessment,1,2,2,NA,RSG1,1,RS_DSRESP,Is the subject classified to be a Responder according to protocol?,50.0,Yes,1,2023-01-09 08:29,DM3,Initial Data Entry
